Radiopharm - anyone know how this compares to TLX?, page-38

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02537488-2A1382552?access_token=83ff96335c2d45a094df02a206a39ff4

https://www.radiopharmtheranostics.com/news

Radiopharm Theranostics extends agreement for Australian prostate cancer trial with GenesisCare

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has extended its agreement with global oncology provider GenesisCare, who will support a second Radiopharm clinical trial in Australia.

The trial will use Radiopharm’s PSA targeting antibody to start a therapeutic Phase 1 in prostate cancer, with an expected commencement in the coming months. The innovative approach and novel mode of action compared with other treatments currently under development make Radiopharm’s technology highly prospective.

Discovered by Professor David Ulmert, previously at Memorial Sloan Kettering and now UCLA, the proprietary monoclonal antibody is capable of targeting free human prostate kallikrein (PSA) in prostate cancer cells. The antibody platform enables a radiotheranostic applicable therapy of prostatic cancer through radioimmunotherapy and diagnosis of advanced prostate cancer.

GenesisCare is a leading provider of integrated oncology care globally, with more than 440 locations in Australia, UK, the USA and Spain. GenesisCare’s global innovation programs aim to bring novel therapies and precision medicine to more cancer patients in need to achieve the best possible life outcomes.

“GenesisCare is a leader in cancer care and to further the relationship with the Company adds to our confidence as we move through the various steps in our clinical development,” said Radiopharm’s CEO & Managing Director Riccardo Canevari.

“We look forward to getting to work on these trials and bringing updates to the market as they